Skip to main
PRME

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc. is advancing its innovative genetic medicine development, with strong prospects indicated by preclinical success in its program PM577 for Wilson Disease, which demonstrates targeted gene correction in animal models and a pathway to enhance patient outcomes. The company's focus on the alpha-1 antitrypsin deficiency (AATD) program underlines its potential as a best-in-class solution in a market lacking disease-modifying treatments, presenting significant commercial opportunities. Additionally, upcoming regulatory milestones, including potential approvals and partnerships, alongside positive peer valuations, suggest a promising upside for Prime Medicine's stock over the next 12-15 months.

Bears say

The financial outlook for Prime Medicine Inc is adversely affected by uncertainties surrounding the regulatory approval of its key products, PM577 and PM647. Despite the company's promising preclinical results, the risk remains that even successful endpoints may not lead to regulatory acceptance, resulting in potential downward revisions of financial projections. Furthermore, any complexities or delays in the regulatory pathway could further exacerbate the situation, negatively impacting the company's financial projections and overall valuation.

PRME has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 5 analysts, PRME has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.